Abstract
The mammalian target of rapamycin (mTOR) is a PI3K-related serine/threonine kinase and plays a critical role in modulating proliferation, growth, survival, invasion and chemoresistance of multiple myeloma, a malignancy of plasma cells. Since it was identified as the therapeutic target of rapamycin, mTOR has been applied for anti-cancer drug discovery. More and more mTOR inhibitors have been developed and demonstrated with great clinical potentials for multiple myeloma and other cancers. In this review, we highlighted advances in drug discovery targeting the mTOR signaling pathway for the treatment of multiple myeloma with an input from our recent studies.
Keywords: Mammalian target of rapamycin (mTOR), mTOR complex 1, mTOR complex 2, multiple myeloma, drug discovery.
Current Pharmaceutical Design
Title:The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma
Volume: 20 Issue: 1
Author(s): Jie Li, Jingyu Zhu, Biyin Cao and Xinliang Mao
Affiliation:
Keywords: Mammalian target of rapamycin (mTOR), mTOR complex 1, mTOR complex 2, multiple myeloma, drug discovery.
Abstract: The mammalian target of rapamycin (mTOR) is a PI3K-related serine/threonine kinase and plays a critical role in modulating proliferation, growth, survival, invasion and chemoresistance of multiple myeloma, a malignancy of plasma cells. Since it was identified as the therapeutic target of rapamycin, mTOR has been applied for anti-cancer drug discovery. More and more mTOR inhibitors have been developed and demonstrated with great clinical potentials for multiple myeloma and other cancers. In this review, we highlighted advances in drug discovery targeting the mTOR signaling pathway for the treatment of multiple myeloma with an input from our recent studies.
Export Options
About this article
Cite this article as:
Li Jie, Zhu Jingyu, Cao Biyin and Mao Xinliang, The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma, Current Pharmaceutical Design 2014; 20 (1) . https://dx.doi.org/10.2174/13816128113199990638
DOI https://dx.doi.org/10.2174/13816128113199990638 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peptide-Based Anticancer Vaccines: Recent Advances and Future Perspectives
Current Medicinal Chemistry Clinical Development of mTOR Inhibitors: A Focus on Lymphoma
Reviews on Recent Clinical Trials Clinical Phenotypes of Severe Cutaneous Drug Hypersensitivity Reactions
Current Pharmaceutical Design Phosphorothioate Oligonucleotides: Effectiveness and Toxicity
Current Drug Targets AZT: An Old Drug with New Perspectives
Current Clinical Pharmacology Last Findings on Dual Inhibitors of Abl and Src Tyrosine-Kinases
Mini-Reviews in Medicinal Chemistry Monocyte Dependent Regulation of Autoimmune Inflammation
Current Molecular Medicine Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity
Current Medicinal Chemistry Cell-and Gene-based Therapeutic Approaches for Neurological Deficits in Mucopolysaccharidoses
Current Pharmaceutical Biotechnology Advances in Stem Cell Therapy for Leukemia
Current Stem Cell Research & Therapy The Multiple Facets of Hematopoietic Stem Cells
Current Neurovascular Research Novel Anticancer Targets and Drug Discovery in Post Genomic Age
Current Medicinal Chemistry - Anti-Cancer Agents Clozapine Induced Eosinophilia in a Case of Schizoaffective Disorder
Current Psychopharmacology Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations
Current Medicinal Chemistry Promising Therapies in Sickle Cell Disease
Cardiovascular & Hematological Disorders-Drug Targets Tyrosine Kinases as Targets for Anti-Inflammatory Therapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Metalloprotein Inhibitors for the Treatment of Human Diseases
Current Topics in Medicinal Chemistry Disease Modification in Rheumatoid Arthritis and Osteoarthritis-Current and Emerging Targets and Therapeutics
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Antimicrobial Action of Chelating Agents: Repercussions on the Microorganism Development, Virulence and Pathogenesis
Current Medicinal Chemistry Flavonoids Protect Cerebrovascular Endothelial Cells through Nrf2 and PI3K from β-Amyloid Peptide-Induced Oxidative Damage
Current Neurovascular Research